General Oncology
Massachusetts-based General Oncology develops treatments for metastatic cancers, currently conducting a clinical trial for BRCA-related pancreatic cancer.
- 7
- Private company
- Brookline, MA, USUnited States
Massachusetts-based General Oncology develops treatments for metastatic cancers, currently conducting a clinical trial for BRCA-related pancreatic cancer.
generaloncology.comCrawled Oct 9, 2026
Dr. Eileen M. O'Reilly reports that a new treatment approach in the SHARON trial demonstrates benefits for patients with advanced pancreatic cancer. The findings highlight a potential therapeutic strategy under investigation for this aggressive disease, where effective treatments remain limited.
Dec 2025curetoday.comNews article
General Oncology presents early Phase 1 data for **GO-4**, a novel regimen combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells. The trial evaluates the treatment in patients with **BRCA-related pancreatic cancer**, showing manageable side effects and early signs of effectiveness. Results were shared at **ESMO 2025**, highlighting potential for a new therapeutic approach in metastatic cancers.
Oct 2025Yahoo FinanceNews article
General Oncology presents Phase 1 SHARON trial results for its GO-4 therapy in patients with BRCA or PALB2 gene mutations. The trial evaluates safety and efficacy in treating associated cancers. Data will be shared at the European Society for Medical Oncology (ESMO) 2025 conference.
Oct 2025MedPath TrialNews article
General Oncology forms a Scientific Advisory Board to guide its development of first-in-class oncology therapies. The board includes leading experts in cancer research and drug development. This move supports the company’s clinical-stage pipeline targeting unmet needs in oncology.
Sep 2025GlobeNewswireNews article